AKT1 and cancer: AKT activation driven through PIP3-AKT interaction at plasma membrane and cytoplasmic/nuclear activation of ERK1/2 kinase are the focal points of several signal transduction pathways and reported to impart therapy resistance in various cancers including HGSOC [11], [12], [13], [14].